Skip to Content

MK-8237 Approval Status

  • FDA approved: No
  • Brand name: MK-8237
  • Company: Merck & Co., Inc.
  • Treatment for: House Dust Mite Allergy

MK-8237 is a sublingual allergy immunotherapy (SLIT) tablet in development for the treatment of house dust mite-induced allergic rhinitis with or without conjunctivitis.

Development Status and FDA Approval Process for MK-8237

Apr 12, 2016Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.